Tango Therapeutics, Inc.

NASDAQ:TNGX

Biotechnology

Healthcare
$21.89 -10.03%

-$3.24 today

Market cap
$3.71B
Beta
1.19
P/E (TTM)
-38.9
EPS (TTM)
-$0.75
52W Low $4.60High $34.39

Volume 2.75M

Average 3.67M

TNGX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Tango Therapeutics, Inc.NASDAQ: TNGX

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) growth accelerates

Q3 FY2026 weighted avg shares (diluted) of 173.93M shares rose 56.7% year over year, ahead of the +32.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 16.0% from the prior quarter. Over 3 fiscal years it compounded at +9.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +56.7% holds above the trailing-twelve-month pace of +32.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
173.93M+16.0% QoQ
Last fiscal yearDec 2025
116.17M+6.4% YoY
LTMSep 2026
145.89M+32.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+56.7%——
1 year+6.4%——
3-year CAGR+9.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
116.17M USD
Year-over-year change
+6.4%
4-year CAGR
+16.9%

Weighted Avg Shares (Diluted) vs competitors

How TNGX compares with its peers on the latest reported figures

  • TNGX's LTM Sep 2026 weighted avg shares (diluted) of 145.89M shares is the 5th highest of the 11 companies compared; the peer median is 102.35M shares.
  • Its year-over-year change of +32.5% is the 2nd highest of 11, against a peer median of +9.6%.
  • Over three fiscal years its annual growth of +9.8% compares with a peer median of +20.0%.
TNGX Competitors Peer median
Weighted Avg Shares (Diluted) for TNGX and competitors
Company Period LTM YoY 3-year CAGR
NUVBNuvation Bio Inc.LTM Jun 2026353.26M +9.5%+16.4%
ERASErasca, Inc.LTM Sep 2026310.86M +9.7%+32.5%
RVMDRevolution Medicines, Inc.LTM Jun 2026197.09M +10.9%+33.1%
RLAYRelay Therapeutics, Inc.LTM Jun 2026181.67M +12.1%+15.2%
TNGXTango Therapeutics, Inc.LTM Sep 2026145.89M +32.5%+9.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026108.1M +31.0%+21.3%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
IDYAIDEAYA Biosciences, Inc.LTM Mar 202688.86M +4.6%+28.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 202674.4M -1.9%+17.6%
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 202638.56M +2.3%+20.7%
Peer median (excluding TNGX) 102.35M+9.6%+20.0%

Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.04M24.86M36.53M42.07M62.38M
Cost of Revenue00002.28M
Gross Profit37.04M24.86M36.53M42.07M60.1M
Gross Margin100.0%100.0%100.0%100.0%96.3%
Research & Development77.64M105.91M115.2M143.92M132.17M
Selling, General & Admin17.6M30.03M35.5M43.75M41.51M
Operating Expenses95.23M135.93M150.7M187.66M171.39M
Depreciation & Amortization897K1.61M2.42M2.5M2.28M
EBITDA(57.05M)(106.51M)(99.2M)(127.6M)(99.31M)
EBITDA Margin-154.0%-428.5%-271.6%-303.3%-159.2%
Operating Income(58.19M)(111.07M)(114.17M)(145.6M)(111.29M)
Operating Margin-157.1%-446.8%-312.6%-346.1%-178.4%
Interest Income495K1.46M6.62M7.89M5.63M
Interest Expense00000
Other Income / Expenses247K2.95M12.56M15.5M9.7M
Income Before Tax(57.94M)(108.12M)(101.61M)(130.09M)(101.59M)
Pre-Tax Margin-156.4%-434.9%-278.2%-309.2%-162.8%
Income Tax Expense292K54K134K208K4K
Net Income(58.24M)(108.18M)(101.74M)(130.3M)(101.59M)
Net Margin-157.2%-435.1%-278.5%-309.7%-162.9%
EPS (Basic)(0.94)(1.23)(1.08)(1.19)(0.87)
EPS (Diluted)(0.94)(1.23)(1.08)(1.19)(0.87)
Weighted Avg Shares62.11M87.82M94.57M109.23M116.17M
Weighted Avg Shares (Diluted)62.11M87.82M94.57M109.23M116.17M

Tango Therapeutics, Inc.

NASDAQ:TNGX

Intrinsic Alpha fair value

Locked

Current Price

$21.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.